KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company, today announced the closing of its previously announced underwritten public offering of 7,475,000 shares of its common stock, including 975,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $9.75 per share. The gross proceeds from the offering were $72.9 million, before deducting customary underwriting discounts and commissions and offering expenses.
Help employers find you! Check out all the jobs and post your resume.
